NYSE:CBM - Cambrex Stock Price, News, & Analysis Sign in or create an account to add this stock to your watchlist. Get Started $63.85 +1.05 (+1.67 %) (As of 08/21/2018 01:19 PM ET)Previous Close$63.00Today's Range$62.35 - $64.0052-Week Range$42.55 - $67.75Volume10,809 shsAverage Volume441,359 shsMarket Capitalization$2.11 billionP/E Ratio20.09Dividend YieldN/ABeta2.4 Company ProfileAnalyst RatingsChartEarnings HistoryFinancialsInsider TradesHeadlinesOptions ChainSEC FilingsSocial Media Share on FacebookShare on TwitterShare on LinkedInShare on RedditShare on StocktwitsPrint this articleShare by Email Cambrex Corporation, a life sciences company, provides various products and services for the development and commercialization of new and generic therapeutics worldwide. Its products comprise active pharmaceutical ingredients and pharmaceutical intermediates that are used in the production of prescription and over-the-counter drug products, as well as other fine chemicals. The company serves generic drug companies; and companies that discover and commercialize small molecule human therapeutics. The company sells its products directly, as well as through independent agents. Cambrex Corporation was founded in 1981 and is headquartered in East Rutherford, New Jersey. Receive CBM News and Ratings via Email Sign-up to receive the latest news and ratings for CBM and its competitors with MarketBeat's FREE daily newsletter. Industry, Sector and Symbol Stock Exchange NYSE Industry Pharmaceutical preparations Sub-IndustryLife Sciences Tools & Services SectorMedical SymbolNYSE:CBM CUSIP13201110 Webwww.cambrex.com Phone201-804-3000 Debt Debt-to-Equity RatioN/A Current Ratio5.23 Quick Ratio4.20 Price-To-Earnings Trailing P/E Ratio20.09 Forward P/E RatioN/A P/E Growth1.5 Sales & Book Value Annual Sales$534.46 million Price / Sales3.97 Cash Flow$4.2425 per share Price / Cash15.05 Book Value$16.62 per share Price / Book3.84 Profitability EPS (Most Recent Fiscal Year)$3.17 Net Income$102.45 million Net Margins20.75% Return on Equity22.32% Return on Assets16.44% Miscellaneous Employees1,228 Outstanding Shares33,260,000Market Cap$2.11 billion Cambrex (NYSE:CBM) Frequently Asked Questions What is Cambrex's stock symbol? Cambrex trades on the New York Stock Exchange (NYSE) under the ticker symbol "CBM." How were Cambrex's earnings last quarter? Cambrex Co. (NYSE:CBM) posted its earnings results on Thursday, August, 2nd. The biotechnology company reported $0.74 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $0.69 by $0.05. The biotechnology company earned $152.05 million during the quarter, compared to analyst estimates of $132.78 million. Cambrex had a return on equity of 22.32% and a net margin of 20.75%. The company's revenue for the quarter was up 13.0% compared to the same quarter last year. During the same quarter last year, the firm earned $0.76 earnings per share. View Cambrex's Earnings History. When is Cambrex's next earnings date? Cambrex is scheduled to release their next quarterly earnings announcement on Tuesday, November, 6th 2018. View Earnings Estimates for Cambrex. What guidance has Cambrex issued on next quarter's earnings? Cambrex issued an update on its FY18 earnings guidance on Thursday, August, 2nd. The company provided earnings per share guidance of 2.91-3.14 for the period, compared to the Thomson Reuters consensus earnings per share estimate of $2.85. What price target have analysts set for CBM? 3 brokerages have issued 12 month target prices for Cambrex's shares. Their predictions range from $60.00 to $60.00. On average, they expect Cambrex's share price to reach $60.00 in the next year. This suggests that the stock has a possible downside of 5.8%. View Analyst Price Targets for Cambrex. What is the consensus analysts' recommendation for Cambrex? 3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Cambrex in the last year. There are currently 1 hold rating and 2 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Cambrex. Who are some of Cambrex's key competitors? Some companies that are related to Cambrex include Valeant Pharmaceuticals (VRX), Bausch Health Companies (BHC), SAGE Therapeutics (SAGE), Ionis Pharmaceuticals (IONS), Alkermes (ALKS), Amneal Pharmaceuticals (AMRX), Dr.Reddy's Laboratories (RDY), United Therapeutics (UTHR), Catalent (CTLT), Ligand Pharmaceuticals (LGND), GALAPAGOS NV/S (GLPG), FibroGen (FGEN), Loxo Oncology (LOXO), Agios Pharmaceuticals (AGIO) and Taro Pharmaceutical Industries (TARO). Who are Cambrex's key executives? Cambrex's management team includes the folowing people: Mr. Steven M. Klosk, Pres, CEO & Director (Age 61)Mr. Tom G. Vadaketh, Exec. VP & CFO (Age 55)Mr. Shawn P. Cavanagh, Exec. VP & COO (Age 52)Ms. Samantha M. Hanley, VP, Gen. Counsel & Corp. Sec. (Age 40)Mr. Gregory P. Sargen, Exec. VP of Corp. Devel. & Strategy (Age 52) Has Cambrex been receiving favorable news coverage? News articles about CBM stock have trended positive this week, Accern reports. The research firm ranks the sentiment of news coverage by analyzing more than twenty million news and blog sources in real time. Accern ranks coverage of companies on a scale of negative one to one, with scores nearest to one being the most favorable. Cambrex earned a media and rumor sentiment score of 0.33 on Accern's scale. They also gave media coverage about the biotechnology company an impact score of 46.40 out of 100, meaning that recent news coverage is somewhat unlikely to have an impact on the stock's share price in the next few days. View Recent Headlines for Cambrex. Who are Cambrex's major shareholders? Cambrex's stock is owned by many different of institutional and retail investors. Top institutional shareholders include BlackRock Inc. (13.90%), Bank of New York Mellon Corp (4.47%), Dimensional Fund Advisors LP (4.27%), American Capital Management Inc. (2.19%), Boston Partners (2.12%) and Brown Advisory Inc. (1.98%). Company insiders that own Cambrex stock include Gregory Sargen, Ilan Kaufthal, Leon J Hendrix Jr, Samantha Hanley, Shawn Cavanagh and Steven M Klosk. View Institutional Ownership Trends for Cambrex. Which major investors are selling Cambrex stock? CBM stock was sold by a variety of institutional investors in the last quarter, including Brown Advisory Inc., Eqis Capital Management Inc., Granite Investment Partners LLC, US Bancorp DE, Connor Clark & Lunn Investment Management Ltd., Peregrine Capital Management LLC, Royce & Associates LP and King Luther Capital Management Corp. Company insiders that have sold Cambrex company stock in the last year include Gregory Sargen, Ilan Kaufthal, Samantha Hanley, Shawn Cavanagh and Steven M Klosk. View Insider Buying and Selling for Cambrex. Which major investors are buying Cambrex stock? CBM stock was acquired by a variety of institutional investors in the last quarter, including Investment Counselors of Maryland LLC, BlackRock Inc., Wells Fargo & Company MN, Acadian Asset Management LLC, FMR LLC, Rice Hall James & Associates LLC, Cambiar Investors LLC and Millennium Management LLC. View Insider Buying and Selling for Cambrex. How do I buy shares of Cambrex? Shares of CBM can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab. What is Cambrex's stock price today? One share of CBM stock can currently be purchased for approximately $63.70. How big of a company is Cambrex? Cambrex has a market capitalization of $2.11 billion and generates $534.46 million in revenue each year. The biotechnology company earns $102.45 million in net income (profit) each year or $3.17 on an earnings per share basis. Cambrex employs 1,228 workers across the globe. How can I contact Cambrex? Cambrex's mailing address is ONE MEADOWLANDS PLZ, EAST RUTHERFORD NJ, 07073. The biotechnology company can be reached via phone at 201-804-3000 or via email at [email protected] MarketBeat Community Rating for Cambrex (NYSE CBM)Community Ranking: 2.6 out of 5 ( )Outperform Votes: 185 (Vote Outperform)Underperform Votes: 171 (Vote Underperform)Total Votes: 356MarketBeat's community ratings are surveys of what our community members think about Cambrex and other stocks. Vote "Outperform" if you believe CBM will outperform the S&P 500 over the long term. Vote "Underperform" if you believe CBM will underperform the S&P 500 over the long term. You may vote once every thirty days. This page was last updated on 8/21/2018 by MarketBeat.com StaffFeatured Article: Should you buy a closed-end mutual fund?